<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1197">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03493282</url>
  </required_header>
  <id_info>
    <org_study_id>COG0105</org_study_id>
    <nct_id>NCT03493282</nct_id>
  </id_info>
  <brief_title>Effect of CT1812 Treatment on Brain Synaptic Density</brief_title>
  <official_title>A Pilot Synaptic Vesicle Glycoprotein 2A (SV2A) PET Study to Evaluate the Effect of CT1812 Treatment on Synaptic Density in Participants With Mild to Moderate Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cognition Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cognition Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, randomized, double-blind, placebo-controlled, parallel group study&#xD;
      of two doses of CT1812 in adults with mild to moderate Alzheimer's Disease to evaluate the&#xD;
      safety and tolerability of oral CT1812, administered for up 180 days for the Primary study&#xD;
      and another 180 days for the Double blind extension study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 28, 2018</start_date>
  <completion_date type="Actual">October 16, 2020</completion_date>
  <primary_completion_date type="Actual">October 16, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of study participants with treatment related adverse events and serious adverse events.</measure>
    <time_frame>Up to 30 weeks</time_frame>
    <description>To evaluate the safety of CT1812 in AD patients by assessing by TEAEs and SAEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in brain synaptic density over a six month period using the SV2A PET ligand 11C-UCB-J.</measure>
    <time_frame>Up to 30 weeks</time_frame>
    <description>Evaluating the effect of CT1812 on brain synaptic density over 30 week time period in Alzheimer's disease (AD) patients using the SV2A PET ligand 11C-UCB-J</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Active Treatment- CT1812 100 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>7 subjects randomized to 100 mg CT1812</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Treatment- CT1812 300 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>7 subjects randomized to 300 mg CT1812</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>7 subjects randomized to matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active Treatment- CT1812 100 mg</intervention_name>
    <description>Active Study Drug</description>
    <arm_group_label>Active Treatment- CT1812 100 mg</arm_group_label>
    <other_name>Study Drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Non-active study drug</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Matching placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active Treatment- CT1812 300 mg</intervention_name>
    <description>Active Study Drug</description>
    <arm_group_label>Active Treatment- CT1812 300 mg</arm_group_label>
    <other_name>Study Drug</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants may be included in the study only if they meet all of the following&#xD;
             criteria:&#xD;
&#xD;
               1. Men, and women of non-childbearing potential, 50-85 years of age inclusively,&#xD;
                  with a diagnosis of mild to moderate Alzheimer's disease according to the 2011&#xD;
                  NIA-AA criteria and at least a 6 month decline in cognitive function documented&#xD;
                  in the medical record.&#xD;
&#xD;
                    1. Non-childbearing potential for women is defined as postmenopausal [last&#xD;
                       natural menses greater than 24 months; in women under age 55, menopausal&#xD;
                       status will be documented with serum follicle stimulating hormone (FSH)&#xD;
                       test] or undergone a documented bilateral tubal ligation or hysterectomy.&#xD;
&#xD;
                    2. Male participants who are sexually active with a woman of child-bearing&#xD;
                       potential must agree to use condoms during the trial and for 3 months after&#xD;
                       last dose unless the woman is using an acceptable means of birth control.&#xD;
                       Acceptable forms of birth control include abstinence, birth control pills,&#xD;
                       or any double combination of: intrauterine device (IUD), male or female&#xD;
                       condom, diaphragm, sponge, and cervical cap.&#xD;
&#xD;
               2. Neuroimaging (MRI) obtained during screening consistent with the clinical&#xD;
                  diagnosis of Alzheimer's disease and without findings of significant exclusionary&#xD;
                  abnormalities (see exclusion criteria, number 3).&#xD;
&#xD;
               3. MMSE 18-26 inclusive&#xD;
&#xD;
               4. A positive amyloid (Pittsburgh imaging compound B) scan at screening, or history&#xD;
                  of a positive amyloid scan prior to study entry, or prior lumbar puncture with a&#xD;
                  CSF Abeta concentration consistent with Alzheimer's disease.&#xD;
&#xD;
               5. Formal education of eight or more years.&#xD;
&#xD;
               6. Must have a caregiver who sees them at least 10 hours per week, oversees the&#xD;
                  administration of study drug, and is willing and able to oversee administration&#xD;
                  of study medication and participate in all clinic visits and some study&#xD;
                  assessments. The caregiver must provide written informed consent to participate&#xD;
                  in the study.&#xD;
&#xD;
               7. Living at home or in the community (assisted living acceptable)&#xD;
&#xD;
               8. Able to swallow CT1812 capsules.&#xD;
&#xD;
               9. Stable pharmacological treatment of any other chronic conditions for at least 30&#xD;
                  days prior to screening.&#xD;
&#xD;
              10. Capable of providing either written informed consent or oral assent to the study&#xD;
                  procedures and for use of protected health information [Health Insurance&#xD;
                  Portability and Accountability Act (HIPAA) Authorization, if applicable]. If the&#xD;
                  Participant can provide only assent, their legally authorized representative also&#xD;
                  must provide written informed consent. Written informed consent also shall be&#xD;
                  obtained from the responsible caregiver. All consent processes must be undertaken&#xD;
                  in the presence of a witness and prior to any study procedures.&#xD;
&#xD;
              11. Must consent to apolipoprotein E (ApoE) genotyping.&#xD;
&#xD;
              12. Generally healthy with mobility (ambulatory or ambulatory-aided, i.e., walker or&#xD;
                  cane), vision and hearing (hearing aid permissible) sufficient for compliance&#xD;
                  with testing procedures.&#xD;
&#xD;
              13. Able to complete all screening evaluations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants will be excluded from the study if any of the following conditions apply:&#xD;
&#xD;
               1. Hospitalization or change of chronic concomitant medication within one month&#xD;
                  prior to screening.&#xD;
&#xD;
               2. Patients living in a continuous care nursing facility&#xD;
&#xD;
               3. Screening MRI of the brain indicative of significant abnormality, including, but&#xD;
                  not limited to, prior hemorrhage or infarct &gt; 1 cm3, &gt;3 lacunar infarcts,&#xD;
                  cerebral contusion, encephalomalacia, aneurysm, vascular malformation, subdural&#xD;
                  hematoma, hydrocephalus, space-occupying lesion (e.g. abscess or brain tumor such&#xD;
                  as meningioma).&#xD;
&#xD;
               4. MRI incompatible implants and other contraindications for MRI, such as pacemaker,&#xD;
                  artificial joints, non-removable body piercings, etc. Additionally, participants&#xD;
                  who meet the following imaging exclusion criteria will not be included in this&#xD;
                  study:&#xD;
&#xD;
                    1. Claustrophobia that will result in significant anxiety and difficulty lying&#xD;
                       still for brain imaging (MRI or PET).&#xD;
&#xD;
                    2. Participation in other research studies involving ionizing radiation within&#xD;
                       one year of the PET scans that would cause the participant to exceed the&#xD;
                       yearly dose limits for healthy volunteers.&#xD;
&#xD;
                    3. History of IV drug use that would prevent venous access for PET tracer&#xD;
                       injection.&#xD;
&#xD;
                    4. Severe motor problems that prevent the participant from lying still for&#xD;
                       brain imaging.&#xD;
&#xD;
                    5. Severe chronic pain (e.g., as the result of rheumatoid arthritis) that would&#xD;
                       prevent them from lying still during brain imaging.&#xD;
&#xD;
               5. Clinical or laboratory findings consistent with:&#xD;
&#xD;
                    1. Other primary degenerative dementia, (dementia with Lewy bodies,&#xD;
                       fronto-temporal dementia, Huntington's disease, Jacob-Creutzfeld Disease,&#xD;
                       Down's syndrome, etc.)&#xD;
&#xD;
                    2. Other neurodegenerative condition (Parkinson's disease, amyotrophic lateral&#xD;
                       sclerosis, etc.)&#xD;
&#xD;
                    3. Seizure disorder&#xD;
&#xD;
                    4. Other infectious, metabolic or systemic diseases affecting the central&#xD;
                       nervous system (syphilis, present hypothyroidism, present vitamin B12 or&#xD;
                       folate deficiency, other laboratory values) etc.)&#xD;
&#xD;
               6. A current DSM-V diagnosis of active major depression, schizophrenia or bipolar&#xD;
                  disorder. Patients with depressive symptoms successfully managed by a stable dose&#xD;
                  of an antidepressant are allowed entry.&#xD;
&#xD;
               7. Clinically significant, advanced or unstable disease that may interfere with&#xD;
                  outcome evaluations, such as:&#xD;
&#xD;
                    1. Chronic liver disease, liver function test abnormalities or other signs of&#xD;
                       hepatic insufficiency (ALT, AST, total bilirubin &gt; 1.5 x ULN)&#xD;
&#xD;
                    2. Respiratory insufficiency&#xD;
&#xD;
                    3. Renal insufficiency eGFR &lt; 45 mL/min based on the CKD-EPI formula&#xD;
                       (https://www.questdiagnostics.com/home/physicians/egfr-calculator)Heart&#xD;
                       disease (myocardial infarction, unstable angina, heart failure,&#xD;
                       cardiomyopathy within six months before screening)&#xD;
&#xD;
                    4. Bradycardia (&lt;45/min.) or tachycardia (&gt;100/min.)&#xD;
&#xD;
                    5. Poorly managed hypertension (systolic &gt;160 mm Hg and/or diastolic &gt;95 mm Hg)&#xD;
                       or hypotension (systolic &lt;90 mm Hg and/or diastolic &lt;60 mm Hg)&#xD;
&#xD;
                    6. Uncontrolled diabetes defined by HbA1c &gt;8&#xD;
&#xD;
               8. History of cancer within 3 years of screening with the exception of fully excised&#xD;
                  non-melanoma skin cancers or non-metastatic prostate cancer that has been stable&#xD;
                  for at least 6 months.&#xD;
&#xD;
               9. Seropositive for human immunodeficiency virus (HIV).&#xD;
&#xD;
              10. History of acute/chronic hepatitis B or C and/or carriers of hepatitis B&#xD;
                  (seropositive for Hepatitis B surface antigen [HbsAg] or anti-Hepatitis C [HCV]&#xD;
                  antibody).&#xD;
&#xD;
              11. Clinically significant abnormalities in screening laboratory tests, including:&#xD;
&#xD;
                    1. hematocrit less than 33% for males and less than 30% for females&#xD;
&#xD;
                    2. absolute neutrophil cell count of 1200/uL (with the exception of a&#xD;
                       documented history of a chronic benign neutropenia), or platelet cell count&#xD;
                       of &lt; 120,000/uL&#xD;
&#xD;
                    3. INR &gt;1.4 or other coagulopathy, confirmed by repeat.&#xD;
&#xD;
              12. Disability that may prevent the patient from completing all study requirements&#xD;
                  (e.g. blindness, deafness, severe language difficulty, etc.)&#xD;
&#xD;
              13. Women who are fertile and of childbearing potential.&#xD;
&#xD;
              14. Within 4 weeks of screening visit or during the course of the study, concurrent&#xD;
                  treatment with antipsychotic agents (except risperidone ≤1.5 mg/day, quetiapine&#xD;
                  ≤100 mg/day, olanzapine ≤5 mg/day, and aripiprazole ≤10 mg/day), antiepileptics&#xD;
                  (except gabapentin and pregabalin for nonseizure indications), centrally active&#xD;
                  anti-hypertensive drugs (e.g., clonidine, l-methyl dopa, guanidine, guanfacine,&#xD;
                  etc.), opiate analgesics, systemic corticosteroids, psychostimulants,&#xD;
                  antiparkinsonian medications (except for non-parkinsonian indications) and mood&#xD;
                  stabilizers (e.g., valproate, lithium), sedatives and anxiolytics with the&#xD;
                  exception that use of short- to medium-acting benzodiazepines for treatment of&#xD;
                  insomnia is permitted, however, use of sedatives or hypnotics should be avoided&#xD;
                  for 8 hours before administration of cognitive tests.&#xD;
&#xD;
              15. Any disorder that could interfere with the absorption, distribution, metabolism&#xD;
                  or excretion of drugs (e.g. small bowel disease, Crohn's disease, celiac disease,&#xD;
                  or liver disease.)&#xD;
&#xD;
              16. Nootropic drugs except stable AD meds (acetylcholinesterase inhibitors and&#xD;
                  memantine&#xD;
&#xD;
              17. Suspected or known drug or alcohol abuse, i.e. more than approximately 60 g&#xD;
                  alcohol (approximately 1 liter of beer or 0.5 liter of wine) per day indicated by&#xD;
                  elevated MCV significantly above normal value at screening.&#xD;
&#xD;
              18. Suspected or known allergy to any components of the study treatments.&#xD;
&#xD;
              19. Enrollment in another investigational study or intake of investigational drug&#xD;
                  within the previous 30 days or five half-lives of the investigational drug,&#xD;
                  whichever is longer.&#xD;
&#xD;
              20. Previous exposure to anti Aβ vaccines&#xD;
&#xD;
              21. Exposure to passive immunotherapies for AD (e.g. monoclonal antibodies) or BACE&#xD;
                  inhibitors within the previous 180 days.&#xD;
&#xD;
              22. Contraindication to undergoing an LP including, but not limited to: inability to&#xD;
                  tolerate an appropriately flexed position for the time necessary to perform an&#xD;
                  LP; international normalized ratio (INR) &gt; 1.4 or other coagulopathy; platelet&#xD;
                  count of &lt; 120,000/μL; infection at the desired lumbar puncture site; taking&#xD;
                  anti-coagulant medication within 90 days of screening (Note: low dose aspirin is&#xD;
                  permitted); degenerative arthritis of the lumbar spine; suspected&#xD;
                  non-communicating hydrocephalus or intracranial mass; prior history of spinal&#xD;
                  mass or trauma.&#xD;
&#xD;
              23. Use of NSAIDs more than 2 days in within any 7-day period. Each incidence of use&#xD;
                  must be recorded in the source and CRF.&#xD;
&#xD;
              24. Any condition, which in the opinion of the investigator or the sponsor makes the&#xD;
                  patient unsuitable for inclusion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher van Dyck, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2022</verification_date>
  <study_first_submitted>February 14, 2018</study_first_submitted>
  <study_first_submitted_qc>April 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2018</study_first_posted>
  <last_update_submitted>January 10, 2022</last_update_submitted>
  <last_update_submitted_qc>January 10, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>July 13, 2022</submitted>
    <returned>August 8, 2022</returned>
    <submitted>October 11, 2022</submitted>
    <returned>November 4, 2022</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

